Evaluation of immune protective efficacy of recombinant adenovirus vector vaccine containing RBS of influenza virus subtype H1N1

Key Points

• The recombinant adenovirus vaccine shows significant immune protection against the H1N1 influenza virus, enhancing overall efficacy.
• Protection is notably higher in vaccinated models with an immune response rating of 75% observed within four weeks post-vaccination.
• Assessment using recombinant adenovirus vector shows promising results in mitigating H1N1 viral infections in controlled settings.
• These findings may enable the development of effective influenza vaccines, though further external validation is necessary.